This Phase 2 study had Nektar Therapeutics testing the effectiveness of rezpegaldesleukin in treating patients with moderately-to-severely active systemic lupus erythematosus (). Rezpegaldesleukin is a drug for treating certain autoimmune diseases.
The bad news hitting NKTR stock today is that the Phase 2 clinical trial failed to meet its primary endpoint. Specifically, rezpegaldesleukin failed to reach a “4-point reduction in the SLEDAI-2K score.” As a result, Nektar’s development partner doesn’t intend to move the treatment forward with a Phase 3 development for SLE.
Brian Kotzin, Chief Medical Officer of Nektar, said the following about the study results:
“We believe that these study results seen in the ISLAND study show that rezpegaldesleukin had a positive impact on disease activity in patients with moderately-to-severely active systemic lupus erythematosus […] These data also further support rezpegaldesleukin’s ability to expand regulatory T cells and the potential for this T regulatory cell stimulator to be used as a novel approach in the field of autoimmune disease.”
How This Affects NKTR Stock
Shares of NKTR stock are falling today following the clinical trial news. That makes sense considering the poor results. While there is a Phase 2b trial planned for rezpegaldesleukin, some investors may not want to stick around for that trial to finish.
NKTR stock is down 38.9% as of Friday morning.
Investors looking for more of the latest stock market news are in the right place!
We’ve got all of the hottest stock market coverage traders need to know about on Friday! That includes why shares of SELLAS Life Sciences (NASDAQ:SLS), Bridger Aerospace (NASDAQ:BAER) and Cingulate (NASDAQ:CING) stock are moving today. You can find more on these matters at the following links!
More Friday Stock Market News
- Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
- Why Is Bridger Aerospace (BAER) Stock Up 84% Today?
- Why Is Cingulate (CING) Stock Up 72% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.